UPDATED COMPANY PRESENTATION – FEBRUARY 2023

Bio-Gene Technology Limited (ASX: BGT, "Bio-Gene") is releasing the attached Updated Company Presentation in anticipation of a series of ongoing Company briefings which will take place over the next couple of weeks.

The Presentation is on the Bio-Gene website and attached.

Approved for release by the Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:		<u>IR/Media</u>
Richard Jagger	Roger McPherson	Rudi Michelson
Chief Executive Officer	CFO & Company Secretary	Monsoon Communications
P: 03 9068 1062	P: 03 9068 1062	P: 03 9620 3333
E: <u>bgt.info@bio-gene.com.au</u>	E: <u>bgt.info@bio-gene.com.au</u>	E: <u>rudim@monsoon.com.au</u>

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g., kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer products. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

BIO-GENE TECHNOLOGY LIMITED

Addressing the needs of an impending catastrophic problem of pest resistance through the development of unique chemistry

PRESENTED BY

Richard Jagger

CEO

BIO-GENE



DISCLAIMER

This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to apply for or purchase securities in the Company or as a recommendation or inducement to make an offer or invitation in respect of securities in the Company. No agreement to subscribe for securities will be entered into on the basis of this presentation or any information contained in this presentation.

This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of another jurisdiction. This presentation is provided for general information purposes only and is selective, does not purport to contain all relevant information and has not been independently verified.

Neither the Company nor its advisors have any responsibility or obligation to inform any recipient of any matter arising or coming to their notice after the date of this presentation, which may affect any matter referred to in the presentation. The Company releases material information as announcements to the ASX (ASX:BGT). Recipients seeking further information in respect of the Company should review the Company's announcements as released to ASX from time to time.

Nothing in this presentation constitutes investment, legal, tax, accounting or other advice. The recipient should consider its own financial situation, objectives and needs and conduct its own independent investigation and assessment, including obtaining investment, legal, tax, accounting or other advice as it considers necessary or appropriate.

The distribution of this presentation (including electronic copies) outside Australia may be restricted by law and persons who come into possession of this presentation outside Australia should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitution a violation of applicable securities laws.

This presentation may contain statements relating to intentions, future acts and events (Forward Looking Statements). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed. no representation, warranty or guarantee, express or implied, is given that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable.

No financial information (unless also contained in financial reports released to ASX), estimates or projections contained in this presentation or as derived from such financial information, estimates or projections can be relied upon as a promise or representation as to any present or future matter.

To the maximum extent permitted by law, neither the Company nor any of its associates, directors, officers, employees, advisors or representatives make any representation or provide any warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation or any subsequent information provided to the recipient including, but not limited to, any financial projections, estimates or other historical information.

OUR VALUE PROPOSITION

VISION:

We want to contribute to a world that provides a viable future with enhanced quality of life for everyone. We will do so by creating solutions to address the impact of insects and other pests on food security and good health

MISSION:

Revolutionising the impact of insect damage in food security and public health settings by developing methods of dealing with insecticide resistance in a safe effective and environmentally friendly manner

Bio-Gene has a Compelling Value Proposition



Natural chemistry is significantly growing in demand by consumers and suppliers



Novel Mode of Action unseen before, proven efficacy



In late 2022 confirmed ability to manufacture at commercial scale



Third-party validation of technology by multiple tier-1 partners Clark Evergreen STK



Strong IP Portfolio with patents out to 2038

Market Cap of \$18.0m (Dec 31st)



Cash at Bank of \$4.3m providing 12-month runway (plus \$443K R&D rebate)



\$31.1bn global opportunity for insecticides across five verticals

OUR STRATEGIC OBJECTIVE



Securing the active ingredient product registrations



licensing fees, milestone payments and royalties by

Bring our unique chemistry to market in partnership with major

players and generate multiple revenue streams from technology

Working with strong commercial partners on product development; marketing and distribution

Developing proprietary manufacturing and production know-how



Potential partnership agreements across multiple geographies and different end-use markets, with collaboration programs now underway in two of our target segments

ADDRESSING SIGNIFICANT GLOBAL CHALLENGES

The effectiveness of current insecticides is diminishing due to resistance & concerns relating to safety profiles



"Without Crop Protection, crop losses would double each year" CropLife



"No new public health insecticides have been developed for mainstream vector control for 30 years"

CDC⁴

Food Security & Public Health

Growing Population	Current global population is 8 billion, growing at 70 million p.a. It is anticipated that global population will reach nearly 10 billion by 2050 ¹ .
Challenges Of Climate Change	Climbing average temperatures & other weather events impact food production per hectare, increase the habitable environment for mosquitoes
Financial Impact	
Production	Currently 20-40% of food produced globally is lost to pests, valued at around US 2000 billion p.a. ^{2,3,4} .
Cost/Benefit	Direct costs due to Malaria infections valued at US\$12 billion p.a., with economic impact many times that ⁵
Social Impact	
Vector Borne Disease	More than half the world is at risk ^{6;} account for 25% of infectious diseases & exacerbate poverty & economic hardship. Potential to grow beyond 50% under climate change scenarios ⁷
Less Arable Land	Increased population puts pressure on available land & resources to produce food for today and tomorrow


- 4. Food & Agriculture Oranization of the United Nations, 2023
- 5. CDC: Malaria's impact worldwide
- 6. WHO report, 2015
- 7. 6. IPCC6th assessment report: Climate Change 2022: Impacts, Adaptation and Vulnerability, February 2022

^{1.} United Nations, "World Population Prospects 2019"

^{2.} Oerke EC, Crop Losses to pest J. Agri Sci 144: 31-43 (2005)

^{3.} Pimentel D Pesticides and Pest controls. In: Peshin R, Dhawan AK. (eds). Integrated pest management: innovation-development process, 1:83-87. Springer Science (2009)

OUR TECHNOLOGY ADDRESSES THESE CHALLENGES AND TARGETS GROWING GLOBAL MARKETS



Bio-Gene's insecticide platform has potential application in large, global market segments estimated to represent a total addressable market valued at over US\$31.1 billion



OUR TECHNOLOGY PLATFORM

We are developing two products that allow entry into five key market segments

Qcide™

Natural Compound

An extract of a specific cultivar of eucalypt, the Gypmie Messmate

Trees are farmed in concentration by sub-contractors in QLD

The leaves contain oil expressing high levels of Tasmanone, a natural compound that has shown evidence of insecticide efficacy



Flavocide™

Nature Identical Compound

BGT has developed a proprietary chemical process with CSIRO to to deliver another Beta-Triketone; a nature identical compound that is able to be produced at commercial scale



Both of our products have potential application in all five of our target market segments

CURRENT PARTNERSHIP – PUBLIC HEALTH: CLARKE MOSQUITO CONTROL

Clarke is the largest vertically integrated company in public health mosquito control

Results of Phase 2 Testing

Very positive results indicated the suitability of Bio-Gene products as mosquito control technology

Target formulations identified for progression to Phase 3 field trials

Confidence for both companies to move forward with commercial development

Commercial Development Agreement Signed

Development of novel formulations

Phase 3 field testing

Agreement is for the U.S. market

Cost of studies borne by Clarke, with shared report of results

Next Steps

Clarke undertaking Phase 3 trials (somewhat weather dependent) using new formulations

Field studies designed to confirm suitability of laboratory developed formulations for field use & EPA registration

Excellent collaboration between the two companies

Market Opportunity

Initial Field of Use: US\$100m¹

Global market \$650m¹



CURRENT PARTNERSHIP – CONSUMER PRODUCTS: EVERGREEN GARDEN CARE

Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand

Initial Field of Use

Fly & mosquito electric evaporator Ant bait gel and ant spray ROFR to negotiate additional

applications within consumer market

Initial Territory

E.U., U.K., A/NZ

ROFR to negotiate additional territories within consumer market



Other market opportunities

With Evergreen we are actively exploring additional market opportunities to add to our agreement

Revenue Model

Up-front licence fee

Milestone payments prior to registration

On-going royalties on end-use product sales

Development costs borne by Evergreen

Next Steps

Continue development of market opportunities

Collaborate on registration activities

Strong relationship is emerging between the two companies

Market Opportunity

Initial Field of Use: US\$600m¹

Total European consumer insecticide market: US\$2b¹

NEW AGREEMENT SIGNED WITH STK BIO-AG CROP PROTECTION, AQUACULTURE & PROFESSIONAL TURF

Key Value Points for Bio-Gene

Licencing arrangements

Bio-Gene grant STK a world-wide nonexclusive licence to develop Qcide for Crop Protection, aquaculture, & professional turf & ornamental markets

Key markets for Qcide are those that see true value in a 100% natural product – i.e. Public Health & Consumer, both driven by end user sentiment. These (and other markets) have been retained exclusively by Bio-Gene.

Significant market opportunity

Crop Protection globally is a US\$16.6 B p.a. business^{1.}

Flavocide offers the best opportunity for product solutions in this segment. Qcide can be offered to our partners where they identify specific opportunities

Registering Active Ingredient

Under the agreement, STK will fully fund registration costs for Qcide globally, & own A.I. registration

This creates a substantial saving to Bio-Gene on the road to market access.

Bio-Gene has full access to the registration to work with partners exclusively in public health, consumer, animal health etc, & non-exclusively in crop protection, aquaculture & professional turf & ornamental markets

Bio-Gene can focus resources on Flavocide registration

Where we have interest in Crop protection, the focus (& exclusivity) on Flavocide will give us an advantage Bio-Gene retains IP relating to Qcide

Opportunities to expand manufacturing capabilities

STK & Bio-Gene will work together to expand production globally. Our strategy has always included multiple production facilities to manage risk and logistics.

Having STK fund a new facility creates substantial savings in money and resources

Agency Opportunity

Explore agency opportunities for STK products which can create an early revenue stream for Bio-Gene

¹ Fortune business insights, 2021: Crop protection chemicals market size... 2021-2028.



STK applies advanced botanical science and bio-ag technology in the development & commercialisation of natural crop protection solutions for growers worldwide.

Based in Israel & founded 30 years ago, STK has operations and product registrations in more than 30 countries.

OTHER ADDITIONAL OPPORTUNITIES STORED GRAIN PROJECT

Grains Research and Development Corporation (GRDC) Department of Agriculture and Fisheries - Queensland (DAF)

Results of Phase 3 testing

Data show the ability for Flavocide, when used in combination (at low rates) to control the full range of stored grain pests over 9 months for susceptible strains and 3-9 months for resistant strains (commercially acceptable time frame).

Further Discussions

Bio-Gene is discussing next steps with potential partners to progress the commercial development of Flavocide as a stored grain protectant

Bio-Gene is in discussions regarding further support from GRDC






Department of Agriculture and Fisheries Field testing completed Nov/Dec 2021

Final reporting on these results reported in March 2022

Positive outcome allows us to move forward

Significant global potential (A\$1b)¹

EXPECTED KEY VALUATION CATALYSTS - NEXT 6 TO 24 MONTHS



A CLEAR ROAD MAP FOR GENERATING VALUE – MEDIUM TERM 2022-2024

2020-2021

• Efficacy data in

multiple settings

• Advancing safety

and tox testing

Confirming novel

Mode of Action

agreements and

additional MTAs

claims

• Development



- Proof of principle efficacy testing
- Preliminary safety data
- Product formulation concepts
- Testing with 3rd parties



- Manufacturing scaleup of Flavocide & Qcide
 - Building regulatory data package
 - Securing initial agreements with commercial partners (Evergreen & Clarke)
 - Creating additional IP (patents technical know-how

 Additional application testing internal and with partners

- Converting additional MTAs into collaborative development agreements (commercial)
- Applying for formal recognition of novel Mode of Action
- Completing data package for final submission
- Securing additional IP

2024-2026



- First regulatory approval and commercial sales
- Additional registration submissions
- Potential new product development program
- Commercial production of Flavocide & Qcide

POTENTIAL UPFRONT AND MILESTONE PAYMENTS, LICENSING FEES



SUMMARY

- New Mode of Action and "nature identical" technology that delivers solutions critical for pest management globally
- Business model based on controlling IP and registration / partnering with majors.
- Bio-Gene now has commercial validation from three key companies in different market segments crop, consumer, public health
- Third deal with STK represents a significant milestone for Bio-Gene
 - Leaders in development of biological solutions for agriculture & applicable expertise
 - Significant financial commitments that allows Bio-Gene to focus on core opportunities Flavocide (all markets) Qcide (Public Health & Consumer)
 - Potential for distribution rights in Australia/NZ of STK products could deliver early revenue streams
- Strong IP position with a strategy to grow
- Defined regulatory pathway
- Manufacturing capability which can now be applied to additional molecules of interest
- Strong news flow anticipated through 2023 to validate our strategy and deliver further inherent value

ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES

BIO-GENE TECHNOLOGY LIMITED



richardj@bio-gene.com.au www.bio-gene.com.au

